企業レポート

大日本住友製薬:製薬企業分析レポート

Dainippon Sumitomo: Pipeline * Products * Performance * Potential

発行 Espicom Business Intelligence 商品コード 42294
出版日 ページ情報 英文 84 Pages
納期: 即日から翌営業日
価格
こちらの商品の販売は終了いたしました。
Back to Top
大日本住友製薬:製薬企業分析レポート Dainippon Sumitomo: Pipeline * Products * Performance * Potential
出版日: 2010年01月31日 ページ情報: 英文 84 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

製薬、医療機器市場に関する調査会社として権威のある情報を提供するEspicom Business Intelligence(本社:英国)では、大日本住友製薬の業務分析を行った報告書"Dainippon Sumitomo - Prospects to 2010"を発行いたしました。

当報告書では、大日本住友製薬の企業戦略、製品ポートフォリオ、財務実績や、2000年から2010年までの売上データなどを概略下記の構成でお届けいたします。

エグゼクティブサマリー

  • イントロダクション
  • 2005年の財務実績
    • 売上
    • 収益
    • 支出
    • 事業部業績
    • 地域別業績
  • 企業戦略
  • 製品/R&D概要
    • 主要製品
    • R&D戦略
    • R&Dパイプライン概要
    • 売上予測
  • 結論

製品ポートフォリオ/R&D

  • 心血管/呼吸器系
  • 抗感染薬
  • 胃腸薬
  • 抗アレルギー薬
  • ホルモン/生物製剤
  • 中枢神経系
  • 糖尿病
  • その他

付録

  • 財務実績
  • 主な提携
  • インフラ
    • 研究開発施設
    • 生産施設
  • 関連会社/ジョイント・ベンチャー
  • 製品インデックス
目次
Product Code: 1223

Abstract

Dainippon Sumitomo Pharma (DSP) is a research-based pharmaceutical company, headquartered in Osaka, which has resulted from the merger of Dainippon Pharmaceutical (which acts as the surviving company) and Sumitomo Pharmaceutical (a division of Sumitomo Chemical).

The merger was finalised and operations began on 1st October 2005, with the new company becoming the fifth largest pharmaceutical company in Japan. DSP is listed as a consolidated subsidiary of Sumitomo Chemical, which owns 50.1 per cent of the outstanding shares.

Since the merger, DSP is active in a range of therapeutic areas, principally Cardiovascular; Oncology/ Infection; Gastrointestinal; Central Nervous System (CNS); Inflammation/Allergy; and Diabetes. In the future, DSP intends to focus its product base on CNS diseases and the treatment of diabetes and associated complications.

This new strategic analysis report Dainippon Sumitomo: Pipeline " Products " Performance " Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.

Table of Contents

  • Latest Results
  • EXECUTIVE SUMMARY
    • Introduction
    • Current Financial Position
      • Company Performance
      • Business Segment Performance
      • Geographic Performance
    • Company Strategy
      • Acquisitions
      • Key Agreements
    • Product Performance Forecasts
      • Discontinued Products
    • Pipeline Analysis
      • Discontinued R&D Projects
    • Conclusions
  • THERAPEUTIC AREA FOCUS
  • R&D PIPELINE
  • CARDIOVASCULAR
    • Marketed Products
      • Amlodin
      • Avapro
      • Ephedrine Nagai
      • ProRenal
      • Others
    • R&D Projects
    • Growth Forecast
  • ONCOLOGY/INFECTION
    • Marketed Products
      • AmBisome
      • Meropen/Merrem
      • Others
    • R&D Projects
    • Growth Forecast
  • GASTROINTESTINAL
    • Marketed Products
      • Gasmotin
      • Others
    • Growth Forecast
  • CENTRAL NERVOUS SYSTEM
    • Marketed Products
      • Excegran/Exogran/Zonegran/Tremode/Trerief
      • Lonasen
      • Others
  • R&D Projects
    • Lurasidone
    • Ranirestat
    • Growth Forecast
  • INFLAMMATION/ALLERGY
    • Marketed Products
      • Ebastel
      • QVAR
    • R&D Projects
      • SMP-028
      • DSP-3025
    • Growth Forecast
  • DIABETES
    • Marketed Products
      • Seibule
      • Others
    • R&D Projects
      • DSP-3235
      • DSP-7238
      • DSP-8658
      • Repaglinide
    • Growth Forecast
  • OTH ER
    • Marketed Products
      • Growject
      • Replagal
    • R&D Projects
    • SMP-986
  • APPENDIX 1 - FINANCIAL PERFORMANCE
    • Full Year Results 2009
  • APPENDIX 2 - KEY CORPORATE EVENTS
  • APPENDIX 3 - KEY AGREEMENTS
    • Almirall Prodesfarma SA
    • Astellas Pharma
    • AstraZeneca
    • Bristol-Myers Squibb
    • Chelsea Therapeutics International Ltd
    • Conforma Therapeutics Corporation
    • Daewoong Pharmaceutical
    • Eisai
    • Gilead Sciences
    • Idenix Pharmaceuticals Inc
    • Kissei Pharmaceutical Co Ltd
    • Kyorin Pharmaceutical Co Ltd
    • Merck KGaA
    • Mitsubishi Tanabe Pharma Corp
    • Neurocrine Biosciences Inc
    • Novo Nordisk
    • Ono Pharmaceutical
    • Pfizer
    • Protez Pharmaceuticals Inc
    • PsychoGenics Inc
    • Recordati
    • sanofi-aventis
    • Schering-Plough
    • Servier
    • Sunesis Pharmaceuticals Inc
    • Torii Pharmaceutical
  • APPENDIX 4 - INFRASTRUCTURE
    • Research And Development Facilities
    • Manufacturing Facilities
  • APPENDIX 5 - KEY PHARMACEUTICAL
  • SUBSIDIARIES/JOINT VENTURES
    • Subsidiaries
    • Joint Ventures
  • APPENDIX 6 - PRODUCT INDEX

INDEX OF TABLES

  • Principal Operating Results
  • Sales By Business Area
  • Operating Income By Business Area
  • Identifiable Assets By Business Area
  • Sales by Destination
  • Recent Product Approvals
  • Major Products, Therapeutic Areas and Sales
  • Major Cardiovascular Products, 2009
  • Major Oncology/Infection Products, 2009
  • Major Gastrointestinal Products, 2009
  • Major Central Nervous System Products, 2009
  • Major Inflammation/Allergy Product, 2009
  • Major Diabetes Products, 2009
  • Other Products, 2009

INDEX OF CHARTS

  • Sales By Business Area
  • Operating Income By Business Area
  • Sales of Top Ten Products (2004A-2014E)
  • Top Ten Selling Products, 2009
  • Domestic R&D Pipeline
  • Overseas R&D Pipeline
  • Amlodin Sales (2004A-2014E)
  • Avapro Sales (2009A-2015E)
  • ProRenal Sales (2004A-2014E)
  • Ambisome Sales (2007A-2014E)
  • Meropen Sales (2004A-2014E)
  • Gasmotin Sales (2004A-2014E)
  • Excegran Sales (2004A-2014E)
  • Lonasen Sales (2009A-2014E)
  • Ebastel Sales (2004A-2014E)
  • QVAR Sales (2004A-2014E)
  • Sales, Costs and Operating Income
  • Profitability and Research Ratios
  • R&D Expenditure and Capital Expenditure
  • Current Assets, Liabilities and Ratio
  • Assets, Cash and Liquidity
  • Employees and Productivity
Back to Top